PH KOREA 2026

Speakers

Session P1 - EASOPH Session

Stephan Rosenkranz

Univ. of Cologne, Germany

P1-1. Importance of RV adaptation and function in pressure- versus volume-loaded right heart

CV

Chih-Hsin Hsu

National Cheng Kung Univ., Taiwan

P1-2. PH management in Taiwan

CV

Yoshihiro Fukumoto

Kurume Univ. School of Medicine, Japan

P1-3. PH management in Japan

CV

Zhi-Cheng Jing

Guangdong Cardiovascular Institute, China

P1-4. PH management in China

CV

Session P2 – Keynote Lecture for PH: Cutting Edge Treatment Strategies

Samuel G. Rayner

Univ. of Washington, USA

P2-1. Beyond the Numbers: Diagnostic Precision and Biological Endotypes in Pulmonary Arterial Hypertension

CV

Hiromi Matsubara

NHO Okayama Medical Center, Japan

P2-2. Treatment Goals for PAH

CV

Takahiro Hiraide

Keio Univ. School of Medicine, Japan

P2-3. PAH with cardiopulmonary comorbidities: Importance of patient-specific treatment goal

CV

Stephan Rosenkranz

Univ. of Cologne, Germany

P2-4. The changing treatment paradigm in pulmonary hypertension

CV

Session P3 – Global PH Summit: About Overcoming Treatment Hurdles in the World

John Feenstra

Pulmonary Hypertension Research Queensland, Australia

P3-1. Pragmatic Strategies for Overcoming Barriers to Pulmonary Hypertension Care: An Asia-Pacific Perspective

CV

Takahiro Hiraide

Keio Univ. School of Medicine, Japan

P3-2. RNF213 R4810K: Asian-specific poor prognostic factor and its underlying mechanism

CV

Chih-Hsin Hsu

National Cheng Kung Univ., Taiwan

P3-3. Challenges and Opportunities for Non-PAH PH

CV

Ju-Hee Lee

Chungbuk National Univ., Korea

P3-4. The Guideline–Reality Gap: PAH Treatment Hurdles in Korea

CV

Session P5 – All Images about PH

Kye Hun Kim

Chonnam National Univ., Korea

P5-1. Echocardiography

CV

Young Seok Cho

Sungkyunkwan Univ., Korea

P5-2. Nuclear medicine for the diagnosis and treatment response evaluation of pulmonary hypertension

CV

Young Jin Kim

Yonsei Univ., Korea

P5-3. CT and MRI in pulmonary hypertension

CV

Eun Na Kim

Seoul National Univ., Korea

P5-4. Pathology

CV

Session P6 – Joint Session with Korean Society of Echocardiography

Ran Heo

Hanyang Univ., Korea

P6-1. Echo-based Screening and Probability Assessment in Pulmonary Hypertension

CV

Jino Park

Inje Univ., Korea

P6-2. Integration of Echo and RHC: Bridging the Gap in Clinical Practice

CV

Jae-Hyeong Park

Chungnam National Univ., Korea

P6-3. Right heart function and Right Ventricular–Pulmonary Arterial Coupling in Pulmonary Hypertension

Seonhwa Lee

Yonsei Univ., Korea

P6-4. Exercise induced PH: Clinical Significance and Diagnostic Pitfalls

CV

Session P7 – New Disease Modifying Drugs for PH

Hiromi Matsubara

NHO Okayama Medical Center, Japan

P7-1. Treprostinil Palmitil Inhalation Powder as a Treatment for PAH

CV

John Feenstra

Pulmonary Hypertension Research Queensland, Australia

P7-2. Defining Disease Modification in PAH: Do Emerging Therapies Deliver?

CV

Derek Solum

United Therapeutics, USA

P7-3. Ralinepag for the treatment of pulmonary arterial hypertension: results of the ADVANCE Outcomes study

CV

Session P10 - Right Heart Journal Session: It's Right Time to Start RHJ!

Hiromi Matsubara

NHO Okayama Medical Center, Japan

P10-1. Why we need 'RHJ'? From EASOPH's perspectives

CV

Stephan Rosenkranz

Univ. of Cologne, Germany

P10-2. Why we need 'RHJ'? From Global perspectives

CV

Chih-Hsin Hsu

National Cheng Kung Univ., Taiwan

P10-3. How do we develop 'RHJ' to the top soon? From EASOPH's perspectives

CV

Samuel G. Rayner

Univ. of Washington, USA

P10-4. How do we Deliver RHJ to the Top? A Global Perspective

CV
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X